RHOFADE

Peak

oxymetazoline hydrochloride

NDATOPICALCREAM
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1

Clinical Trials (1)

NCT03954444Phase 3Completed

A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"

Started Apr 2019
1,105 enrolled
Rosacea

Loss of Exclusivity

LOE Date
Jun 11, 2035
112 months away
Patent Expiry
Jun 11, 2035

Patent Records (5)

Patent #ExpiryTypeUse Code
7812049
May 2, 2028
U-1959
8883838
Dec 1, 2031
Product
11517560
Jun 11, 2035
U-3494
10335391
Jun 11, 2035
U-2567
9974773
Jun 11, 2035
U-2306